AstraZeneca COVID-19 Vaccine

New research highlights reduced COVID-19 vaccine efficacy in patients on immunosuppressants and hepatitis B antiviral drugs post-liver transplant, suggesting a need for additional vaccination to boost antibody levels. Study findings indicate lower antibody levels in immunocompromised patients compared to healthy controls, with significant differences observed after the third vaccine dose. No significant liver function deterioration was noted post-vaccination, but 23 breakthrough infections occurred. Further investigation into antiviral drugs' influence on vaccine responses is needed.

A review in *Health Science Reports* analyzes COVID-19 vaccine efficacy, safety, and complications in MS patients, finding reduced humoral response with anti-CD20 and S1P drugs, but intact T-cell responses. Severe COVID-19 outcomes are more common in patients on anti-CD20 therapies. Vaccination is safer than infection, with timing adjustments recommended for optimal efficacy, particularly a 12-week delay post anti-CD20 therapy. Side effects in MS patients mirror those in the general population, with rare severe cases noted in the AstraZeneca vaccine.

This study explored autoantibodies in COVID-19 vaccine-related AEFIs, comparing them with other AEFIs, healthy donors, and COVID-19-exposed cases. Recruitment followed SWEDEGENE methodology, focusing on vaccines like Comirnaty, Spikevax, and Vaxzevria. Two subsets of samples were analyzed, with autoantibody detection via bead-based and ELISA assays. Positive responses were confirmed by exceeding specific thresholds or functional analyses. Sampling involved heparinized blood, and statistical analyses were conducted using SPSS and Rstudio.